J&J Medical Connect
TECVAYLI®

(teclistamab-cqyv)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

What is TECVAYLI?

Last Updated: 03/09/2026

SUMMARY

Here is a passage from the TECVAYLI PRESCRIBING INFORMATION and MEDICATION GUIDE which may be helpful to address your question:

What is TECVAYLI?

  • TECVAYLI is a prescription medicine used to treat adults with multiple myeloma that has come back or did not respond to prior treatment1:
    • in combination with daratumumab and hyaluronidase-fihj in people who have received at least one treatment regimen, including a proteasome inhibitor and an immunomodulatory agent.
    • alone in people who have received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
  • It is not known if TECVAYLI is safe and effective in children.1 

ADDITIONAL INFORMATION

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for TECVAYLI.1

 

References

1 TECVAYLI (teclistamab-cqyv) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf